Form 4 for BSX Boston Scientific
Accepted 2024-05-23 00:00:00 ET · period of report 2024-05-22 · accession 0001225208-24-006325 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-05-23 | 2024-05-22 | BSX | Brennan Daniel J. | EVP, CFO | M - OptEx | $21.33 | +64.5K | 288.4K | +29% | +$1.37M |
| DM | 2024-05-23 | 2024-05-22+ | BSX | Brennan Daniel J. | EVP, CFO | S - Sale+OE | $75.57 | -112.1K | 223.9K | -33% | -$8.47M |
| DM | 2024-05-23 | 2024-05-22 | BSX | Brennan Daniel J. | EVP, CFO | M - OptEx | $0.00 | -64.5K | 46.9K | -58% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-22 | M | A | 16,863 | $17.26 | 305,268 | D | — | — | |
| 2 | Common | Common Stock | 2024-05-22 | M | A | 15,642 | $27.09 | 320,910 | D | — | — | |
| 3 | Common | Common Stock | 2024-05-22 | M | A | 15,086 | $16.31 | 335,996 | D | — | — | |
| 4 | Common | Common Stock | 2024-05-22 | M | A | 16,863 | $24.55 | 288,405 | D | — | — | |
| 5 | Common | Common Stock | 2024-05-22 | S | D | 64,454 | $75.91 | 271,542 | D | — | — | (F2) Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $75.512 to $76.22, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 6 | Common | Common Stock | 2024-05-23 | S | D | 47,621 | $75.11 | 223,921 | D | — | — | (F3) Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $74.86 to $75.48, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 7 | Derivative | Stock Option (Right to Buy) | 2024-05-22 | M | D | 16,863 | $0.00 | 55,600 | D | $24.55 · — to 2027-02-28 | 16,863 Common Stock | (F7) Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. |
| 8 | Derivative | Stock Option (Right to Buy) | 2024-05-22 | M | D | 15,086 | $0.00 | 15,087 | D | $16.31 · — to 2025-02-23 | 15,086 Common Stock | (F6) Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. |
| 9 | Derivative | Stock Option (Right to Buy) | 2024-05-22 | M | D | 16,863 | $0.00 | 16,865 | D | $17.26 · — to 2026-02-22 | 16,863 Common Stock | (F5) Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. |
| 10 | Derivative | Stock Option (Right to Buy) | 2024-05-22 | M | D | 15,642 | $0.00 | 46,927 | D | $27.09 · — to 2028-02-15 | 15,642 Common Stock | (F4) Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. |